Ads
related to: narcolepsy treatment- Living With Narcolepsy
Learn How to Manage Living With
Your EDS and/or Cataplexy Today.
- Potential Health Risks
Learn About the Potential Risks
of EDS and/or Cataplexy Treatment.
- Narcolepsy Health
Learn How to Treat Cataplexy
& or EDS in Narcolepsy.
- Treatment Savings Program
Learn How to Save on Your
EDS in Narcolepsy Medication.
- Discover Patient Stories
Learn More About The Daily Life of
Patients Living With Narcolepsy.
- Sign Up for More Info
Receive Important Updates
About EDS/Cataplexy Treatment.
- Living With Narcolepsy
Search results
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
Zacks via Yahoo Finance· 3 hours agoRecent Updates Last month, Alkermes announced positive top-line data from a phase Ib study...
Earnings call: Harmony Biosciences maintains strong growth, eyes future launches By Investing.com
Investing.com· 2 days agoHarmony Biosciences (ticker: HRMY) has reported a solid start to the year with a 30% increase in...
Earnings call: Alkermes reports solid Q1 2024 results, optimistic about pipeline By Investing.com
Investing.com· 18 hours agoThe neuroscience company reported net sales for VIVITROL at $97.7 million, ARISTADA at $78.9...
Needham raises Harmony Biosciences stock target on growth strategy By Investing.com
Investing.com· 1 day ago(NASDAQ: NASDAQ:HRMY) to $52, up from the previous $50, while maintaining a Buy rating on the stock....
Alkermes plc Reports First Quarter 2024 Financial Results
FOX 4 Kansas City· 1 day agoAlkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2024. With these new data now in hand, we plan to initiate a phase 2 study in narcolepsy type 2 in the second half of 2024.
Harmony Biosciences posts 30% revenue growth in Q1 By Investing.com
Investing.com· 2 days agoThe company's adjusted earnings per share (EPS) of $0.88 also surpassed analyst expectations by...
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 day agoHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2024 Earnings Call Transcript April 30, 2024...
Earnings call: Jazz Pharmaceuticals sustains growth with key drivers By Investing.com
Investing.com· 8 hours agoThe company has completed a Biologics License Application (BLA) for zanidatamab in the treatment of...
Sweet Harmony: Neuro biotech buys Epygenix and its epilepsy meds for $35M upfront
FierceBiotech· 2 days agoHarmony Biosciences is adding a suite of epilepsy assets to its pipeline, buying Epygenix for $35 million upfront with more than $600 million in biobucks on the table. The relatively small M ...
Harmony Biosciences Exceeds Analyst Revenue Forecasts While Aligning with EPS Projections in Q1 2024
GuruFocus.com via Yahoo Finance· 2 days agoTheir flagship product, WAKIX (pitolisant), has been a critical driver of revenue growth,...
Ad
related to: narcolepsy treatment